IAVI and Moderna launch first-in-Africa clinical trial of mRNA HIV vaccine
Phase I trial in Rwanda and South Africa aims to evaluate mRNA HIV vaccine antigen for safety and immunogenicity and strengthen regional scientific capacity
Phase I trial in Rwanda and South Africa aims to evaluate mRNA HIV vaccine antigen for safety and immunogenicity and strengthen regional scientific capacity
Collaboration to target bacterial and viral pathogens including HIV, SARS-CoV-2, antimicrobial-resistant pathogens, and tuberculosis
The immunogens being tested in IAVI G002 were developed by scientific teams at IAVI and Scripps Research and will be delivered via Moderna's mRNA technology
Subscribe To Our Newsletter & Stay Updated